Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2016 /
Treatment of relapsed myeloma with novel targeted and immune therapies

16th - 20th Apr 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 05.05.16
Views: 1574

Dr Kenneth Anderson - Dana–Farber Cancer Institute, Boston, USA

Dr Kenneth Anderson meets with ecancertv at AACR 2016 to discuss the past, present and future of myeloma treatment.

Myeloma treatments have benefitted from immunotherapeutic developments in recent years, with survival and quality of life rising across many diseases.

With specific attention to checkpoint inhibitor PDL-1, Dr Anderson summarises the roles and applications of different immune cell types, even approaching an innate anti-tumour response.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation